Profiles
Professor Oliver Hanemann
Chair in Clinical Neurobiology
Peninsula Medical School (Faculty of Health)
Professor Oliver Hanemann can be contacted through arrangement with our Press Office, to speak to the media on these areas of expertise.
- Cancer
- Neurofibromatosis
- Motor neurone disease
- Oncology
- Brain tumour
- Neurology
- Neuroscience
- Clinical trials
- Experimental methods
- Laboratory methods
- Medical/pathological research
- Quantitative research
Email publicrelations@plymouth.ac.uk to enquire.
Biography
Biography
Chair of Clinical Neurobiology
Plymouth University Peninsula School of Medicine and Dentistry
Neurology Consultant
Plymouth Hospital NHS Trust
Qualifications
I trained at Medical School in Hamburg, Glasgow, Johns Hopkins and Harvard. After a DFG research fellowship in molecular neurobiology, in which I cloned the myelin protein PMP22 together with P Spreyer, I was neurology registrar at Medical School in Duesseldorf with Prof Freund. During that period I participated in resolving gene-defect and pathogenesis of the most frequent hereditary neuropathy CMT1A, became lecturer for Neurology and Neurobiology and honorary consultant at that department in 1998 and started work on benign glial tumours. From 2000 I was consultant incl. clinical lead and senior lecturer at the medical school in Ulm with Prof Ludolph continuing my work on benign glia tumours and neuropathies focussing more on motor neuropathies. During that time I was also trained as a medical geneticist. In 2005 I became chair of clinical neurobiology at the Peninsula medical school establishing clinical neurobiology research and administering different independent researcher groups. I successfully bridge basic and clinical sciences. I have been Associate Medical Director for R&D Plymouth Hospital NHS Trust and and Academic lead department of Neurology PHNT
My new role at PU PSMD is Director of the Institute for Translational and Stratified Medicine where my remit is to champion research across traditional boundaries and focus on world-leading research.
Roles on external bodies
Nationally I am neurology lead in the Peninsula Neurooncology network, member NCRI brain tumour group and DeNDRON, (currently research director MND in the SW) member of scientific advisory boards (e.g. CTF, Lord Dowding Fund, Brain Research Trust), member of the council of the British Neuro-Oncology Society (BNOS). I am reviewer for more than 17 international journals including Brain, Cancer Res, Oncogene and Human Mol Gen, and reviewer for a variety of granting agencies incl Wellcome, MRC, CR-UK and DFG.
Key publications
(2010) 'Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4(DCAF1) in the Nucleus' CELL 140, (4) 477-490 , DOI
(2008) 'Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma' Cancer Res 68, (13) 5236-5245 , DOI
(2008) 'Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells' Glia 56, (5) 506-515 , DOI
(2012) 'The role of insulin-like growth factors signaling in merlin-deficient human schwannomas. Ammoun S, Schmid MC, Ristic N, Zhou L, Hilton D, Ercolano E, Carroll C, Hanemann CO. Glia. 2012 Nov;60(11):1721-33. doi: 10.1002/glia.22391. Epub 2012 Jul 20' Glia
(2010) 'ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma' Neuro Oncol. 8, (12) 834-43
(2010) 'ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma' Neuro Onc 12, 834-843
Teaching
Teaching
Staff serving as external examiners
Involved in research SSU's, case units, lectures
External PhD examiner at: University of Exeter, University of Portsmouth, University Cardiff, Universit ät Jena, Universit ät Ulm
Research
Research
Research interests
My own focus is on neuromuscular disease esp. motor neuron disease and neurooncology. I supervised more than 15 PhD students quite a few finished with distinction and started a career in academia. Our current work on motor neuron disease is mainly clinical and includes genotype-phenotype analysis and clinical trials. In neurooncology we focus on cell biology studies to find and validate new therapeutic targets as there is a great medical need to find new treatments (summarized in Hanemann 2008, Ammoun and Hanemann 2011). Following our aim to work translational I also look after many patients with these diseases as a honorary consultant.
Research degrees awarded to supervised students
6 Phd's and 3 MD's finished successfully, 3 co-supervised successfully, 2 current
Grants & contracts
Over 2.1 Million £ previously excluding FEC. Currently Action Medical Research, Brain tumour charities, Dr Hadwen Trust and Samantha Dickson Brain Tumour Trust
Publications
Publications
Key publications
(2010) 'Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4(DCAF1) in the Nucleus' CELL 140, (4) 477-490 , DOI
(2008) 'Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma' Cancer Res 68, (13) 5236-5245 , DOI
(2008) 'Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells' Glia 56, (5) 506-515 , DOI
(2012) 'The role of insulin-like growth factors signaling in merlin-deficient human schwannomas. Ammoun S, Schmid MC, Ristic N, Zhou L, Hilton D, Ercolano E, Carroll C, Hanemann CO. Glia. 2012 Nov;60(11):1721-33. doi: 10.1002/glia.22391. Epub 2012 Jul 20' Glia
(2010) 'ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma' Neuro Oncol. 8, (12) 834-43
(2010) 'ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma' Neuro Onc 12, 834-843
Key publications are highlighted
Journals
Articles
(2022) 'Tauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis: The TUDCA-ALS trial protocol' Frontiers in Neurology 13, , DOI Open access
(2022) 'Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma' Brain , DOI Open access
(2022) 'miR-497 and 219 in blood aid meningioma classification' Journal of Neuro-Oncology 160, (1) 137-147 , DOI
(2022) 'Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation' Genetics in Medicine , DOI Open access
(2022) 'Development of ‘Core Outcome Sets’ for Meningioma in Clinical Studies (The COSMIC Project): protocol for two systematic literature reviews, eDelphi surveys and online consensus meetings' BMJ Open 12, (5) , DOI Open access
(2022) 'The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications' Journal of the Neurological Sciences 436, 120188-120188 , DOI
(2022) 'Clinical trials in pediatric ALS: a TRICALS feasibility study' Amyotrophic lateral sclerosis & frontotemporal degeneration 1-8 , DOI Open access
(2021) 'Human endogenous retrovirus type K promotes proliferation and confers sensitivity to anti-retroviral drugs in Merlin-negative schwannoma and meningioma' Cancer Research , DOI Open access
(2021) 'Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical use' Neurology 10.1212/WNL.00000000-10.1212/WNL.00000000 , DOI Open access
(2021) 'REiNS: Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical use' Neurology , DOI Open access
(2021) 'Biomarkers for differentiating grade II meningiomas from grade I: a systematic review' British Journal of Neurosurgery 1-7 , DOI Open access
(2021) 'Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation' Genetics in Medicine 23, (8) 1506-1513 , DOI Open access
(2021) 'Correction: Combined Inhibition of NEDD8-activating Enzyme and mTOR Suppresses NF2 Loss–driven Tumorigenesis' Molecular Cancer Therapeutics 20, (2) 450-450 , DOI
(2021) 'Measuring coping in people with amyotrophic lateral sclerosis using the Coping Index-ALS: A patient derived, Rasch compliant scale' Journal of the Neurological Sciences 421, 117285-117285 , DOI Open access
(2021) 'Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas' International Journal of Molecular Sciences 22, (2) 560-560 , DOI Open access
(2020) 'Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma' Cancers 12, (11) 3270-3270 , DOI Open access
(2020) 'GATA-4, a potential novel therapeutic target for high-grade meningioma, regulates miR-497, a potential novel circulating biomarker for high-grade meningioma' EBioMedicine 59, 102941-102941 , DOI Open access
(2020) 'A Systematic Approach to Review of in vitro Methods in Brain Tumour Research (SAToRI-BTR): Development of a Preliminary Checklist for Evaluating Quality and Human Relevance' Frontiers in Bioengineering and Biotechnology 8, , DOI Open access
(2020) 'The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma' Cancers 12, (7) 1744-1744 , DOI Open access
(2020) 'Measuring quality of life in ALS/MND: validation of the WHOQOL-BREF' Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 21, (5-6) 364-372 , DOI Open access
(2020) 'HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis' Journal of Clinical Investigation 130, (7) 3848-3864 , DOI Open access
(2020) 'A Rapid Robust Method for Subgrouping Non-NF2 Meningiomas According to Genotype and Detection of Lower Levels of M2 Macrophages in AKT1 E17K Mutated Tumours' International Journal of Molecular Sciences 21, (4) 1273-1273 , DOI Open access
(2020) 'Correction to: Do pain, anxiety and depression influence quality of life for people with amyotrophic lateral sclerosis/motor neuron disease? A national study reconciling previous conflicting literature' Journal of Neurology 267, (3) 616-617 , DOI Open access
(2020) 'Constitutive activation of the EGFR–STAT1 axis increases proliferation of meningioma tumor cells' Neuro-Oncology Advances 2, (1) , DOI Open access
(2019) 'Do pain, anxiety and depression influence quality of life for people with amyotrophic lateral sclerosis/motor neuron disease? A national study reconciling previous conflicting literature' Journal of Neurology 267, (3) 607-615 , DOI Open access
(2019) 'DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management' Neuro-Oncology 21, (7) 901-910 , DOI Open access
(2019) 'The relationships between symptoms, disability, perceived health and quality of life in amyotrophic lateral sclerosis/motor neuron disease' Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20, (5-6) 317-327 , DOI Open access
(2019) 'A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis' Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20, (7-8) 584-594 , DOI Open access
(2019) 'Utilization of volumetric magnetic resonance imaging for baseline and surveillance imaging in Neuro-oncology' The British Journal of Radiology 20190059-20190059 , DOI Open access
(2019) 'Trends in phenotype in the English paediatric neurofibromatosis type 2 cohort stratified by genetic severity' Clinical Genetics: an international journal of genetics and molecular medicine 96, (2) 151-162 , DOI Open access
(2019) 'Phase 0 trial investigating the intra-tumoural concentration and activity of Sorafenib in Neurofibromatosis type 2' Journal of Neurology, Neurosurgery and Psychiatry , DOI Open access
(2019) 'Advances in multidisciplinary therapy for meningiomas' Neuro-Oncology 21, (Supplement_1) i18-i31 , DOI
(2019) 'Imaging and diagnostic advances for intracranial meningiomas' Neuro-Oncology 21, (Supplement_1) i44-i61 , DOI
(2019) 'Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life' Neuro-Oncology 21, (Supplement_1) i32-i43 , DOI
(2019) 'Molecular and translational advances in meningiomas' Neuro-Oncology 21, (Supplement_1) i4-i17 , DOI Open access
(2018) 'Proteomic analysis discovers the differential expression of novel proteins and phosphoproteins in meningioma including NEK9, HK2 and SET and deregulation of RNA metabolism' EBioMedicine , DOI Open access
(2018) 'Progression of Hearing Loss in Neurofibromatosis Type 2 According to Genetic Severity' The Laryngoscope , DOI Open access
(2018) 'An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures' Scientific Reports 8, (1) 13537-13537 , DOI Open access
(2018) 'PO-511 High miR-9 levels represent a novel prognostic biomarker to predict development of malignant meningioma' ESMO Open 3, A430-A430 , DOI Open access
(2018) 'Development and validation of Spasticity Index-Amyotrophic Lateral Sclerosis' Acta Neurologica Scandinavica , DOI Open access
(2017) 'An essential role for the tumor suppressor Merlin in regulating fatty acid synthesis' Cancer Research , DOI Open access
(2017) 'Cellular prion protein (PrPC) in the development of Merlin-deficient tumours' Oncogene , DOI Open access
(2017) 'Accumulation of autophagosomes confers cytotoxicity' Journal of Biological Chemistry 13599-13614 , DOI Open access
(2017) 'Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis' Molecular Cancer Therapeutics molcanther.0821.2016-molcanther.0821.2016 , DOI Open access
(2017) 'Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target' EBioMedicine , DOI Open access
(2016) 'A multicentre evaluation of oropharyngeal secretion management practices in amyotrophic lateral sclerosis' Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18, (1-2) 1-9 , DOI
(2016) 'Current status and recommendations for biomarkers and biobanking in neurofibromatosis' Neurology 87, (7 Supplement 1) S40-S48 , DOI Open access
(2016) 'Current whole-body MRI applications in the neurofibromatoses' Neurology 87, (7 Supplement 1) S31-S39 , DOI Open access
(2016) 'Neurocognitive outcomes in neurofibromatosis clinical trials' Neurology 87, (7 Supplement 1) S21-S30 , DOI Open access
(2016) 'Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1' Neurology 87, (7 Supplement 1) S13-S20 , DOI Open access
(2016) 'Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials' Neurology 87, (7 Suppl 1) S4-S12 , DOI Open access
(2016) 'Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis' Oncotarget , DOI Open access
(2016) 'DiPALS: Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis – a randomised controlled trial' Health Technology Assessment 20, (45) 1-186 , DOI Open access
(2015) 'Activation of multiple growth factor signalling pathways is frequent in meningiomas' Neuropathology 36, (3) 250-261 , DOI Open access
(2015) 'The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors' Oncogene 35, (26) 3443-3453 , DOI Open access
(2015) 'PO76GROWTH FACTOR SIGNALLING PATHWAYS IN MENINGIOMAS IS COMMON AND PARTLY DEPENDS ON SUBTYPE ALLOWING FOR STRATIFICATION' Neuro-Oncology 17, (suppl 8) viii14.1-viii14 , DOI
(2015) 'Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial' The Lancet Neurology 14, (9) 883-892 , DOI Open access
(2015) 'Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients' Journal of Medical Genetics 52, (10) 699-705 , DOI
(2015) 'Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study' The Lancet Neurology 14, (7) 702-709 , DOI Open access
(2015) 'Recent Developments in Neurofibromatoses and RASopathies: Management, Diagnosis and Current and Future Therapeutic Avenues' AMERICAN JOURNAL OF MEDICAL GENETICS PART A 167, (1) 1-10 , DOI
(2015) 'The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours' Mol Oncol 9, (1) 236-248 , DOI
(2014) 'IDENTIFICATION AND TARGETING PATHWAYS INVOLVED IN THE DEVELOPMENT OF MERLIN-DEFICIENT TUMOURS' ANTICANCER RESEARCH 34, (10) 5805-5805
(2014) 'THE ROLE OF CELLULAR PRION PROTEIN IN SCHWANNOMA AND OTHER MERLIN-DEFICIENT TUMOURS' ANTICANCER RESEARCH 34, (10) 6123-6123
(2014) 'Artesunate induces necrotic cell death in schwannoma cells' Cell Death Dis 5, (10) , DOI Open access
(2014) 'P06.02 * ACTIVATION OF MULTIPLE GROWTH FACTOR SIGNALLING PATHWAYS IS FREQUENT IN MENINGIOMAS' Neuro-Oncology 16, (suppl 2) ii45-ii45 , DOI
(2014) 'Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus' Cancer Cell 26, (1) 48-60 , DOI
(2014) 'Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2' JOURNAL OF NEUROLOGY 261, (5) 963-969 , DOI Open access
(2014) 'CTF Meeting 2012: Translation of the Basic Understanding of the Biology and Genetics of NF1, NF2, and Schwannomatosis Toward the Development of Effective Therapies' AMERICAN JOURNAL OF MEDICAL GENETICS PART A 164, (3) 563-578 , DOI
(2014) 'Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival' Oncogene 33, (3) 336-346 , DOI Open access
(2013) 'Management of sialorrhoea in motor neuron disease: A survey of current UK practice' AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION 14, (7-8) 521-527 , DOI
(2013) 'Achieving consensus for clinical trials The REiNS International Collaboration' NEUROLOGY 81, (21) S1-S5 , DOI
(2013) 'Achieving consensus for clinical trials: the REiNS International Collaboration' Neurology 81, (21 Suppl 1) S1-S5 , DOI
(2013) 'Conclusions and future directions for the REiNS International Collaboration' NEUROLOGY 81, (21) S41-S44 , DOI
(2013) 'Conclusions and future directions for the REiNS International Collaboration' Neurology 81, (21 Suppl 1) S41-S44 , DOI
(2013) 'Achieving consensus for clinical trials: the REiNS International Collaboration' Neurology 81, (21) S1-S5 , DOI
(2013) 'Δ9-TETRAHYDROCANNABINOL IS PROTECTIVE THROUGH PPARγ DEPENDENT MITOCHONDRIAL BIOGENESIS IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE' J Neurol Neurosurg Psychiatry 84, (11) , DOI Open access
(2013) 'Medulloblastoma in a Patient With the PTPN11 p.Thr468Met Mutation' AMERICAN JOURNAL OF MEDICAL GENETICS PART A 161, (8) 2027-2029 , DOI
(2013) 'Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial' LANCET NEUROLOGY 12, (4) 339-345 , DOI
(2013) 'Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy' NATURE NEUROSCIENCE 16, (4) 426-U86 , DOI
(2013) 'Expression of c-Jun and Sox-2 in human schwannomas and traumatic neuromas' HISTOPATHOLOGY 62, (4) 651-656 , DOI
(2013) 'Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria' AMERICAN JOURNAL OF MEDICAL GENETICS PART A 161A, (3) 405-416 , DOI
(2013) 'Loss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells' Brain 136, (Pt 2) 549-563 , DOI Open access
(2013) 'Conclusions and future directions for the REiNS International Collaboration' Neurology 81, (21 Suppl 1) , DOI
(2012) 'The role of insulin-like growth factors signaling in merlin-deficient human schwannomas' Glia 60, (11) 1721-1733 , DOI Open access
(2012) 'Δ<sup>9</sup>-tetrahydrocannabinol (Δ<sup>9</sup>-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease' Neuropathology and Applied Neurobiology 38, (6) 535-547 , DOI
(2012) 'The role of insulin-like growth factors signaling in merlin-deficient human schwannomas. Ammoun S, Schmid MC, Ristic N, Zhou L, Hilton D, Ercolano E, Carroll C, Hanemann CO. Glia. 2012 Nov;60(11):1721-33. doi: 10.1002/glia.22391. Epub 2012 Jul 20' Glia
(2012) 'Merlin, a multi-suppressor from cell membrane to the nucleus' FEBS Lett 586, (10) 1403-1408 , DOI
(2012) 'Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival' Oncogene 31, (13) 1710-1722 , DOI
(2012) 'Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting' Acta Neuropathol 123, (3) 369-380 , DOI Open access
(2012) 'Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2' Am J Med Genet A 158A, (1) 24-41 , DOI
(2011) 'Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways' Neoplasia 13, (12) 1101-1112 , DOI
(2011) 'Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31]' BMC Neurol 11, , DOI Open access
(2011) 'Cannabinoid receptor and N-acyl phosphatidylethanolamine phospholipase D--evidence for altered expression in multiple sclerosis' Brain Pathol 21, (5) 544-557 , DOI
(2011) 'Changes in iron-regulatory gene expression occur in human cell culture models of Parkinson's disease' Neurochem Int 59, (1) 73-80 , DOI Open access
(2011) 'Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2' Neuro Oncol 13, (7) 759-766 , DOI
(2011) 'Emerging therapeutic targets in schwannomas and other merlin-deficient tumors' Nat Rev Neurol 7, (7) 392-399 , DOI
(2011) 'Cannabinoid Receptor and N-acyl Phosphatidylethanolamine Phospholipase D-Evidence for Altered Expression in Multiple Sclerosis' Brain Pathol 5, 544-557
(2011) 'Changes in iron-regulatory gene expression occur in human cell culture models of Parkinson's disease' Neurochem Int 59, 73-80
(2011) 'Merlin/NF2 Functions Upstream of the Nuclear E3 Ubiquitin Ligase CRL4DCAF1 to Suppress Oncogenic Gene Expression' Scinece Siganlling 4,
(2010) 'Unilateral cerebral hemisphere oedema as a peri-ictal phenomenon' J Neurol 257, (12) 2094-2096 , DOI
(2010) 'Changes in Iron-Regulatory Gene Expression Occur in Human Cell Culture Models of PD' MOVEMENT DISORDERS 25, S628-S628 Open access
(2010) 'ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma' Neuro Oncol. 8, (12) 834-43
(2010) 'ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma' Neuro Oncol 12, (8) 834-843 , DOI
(2010) 'Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4(DCAF1) in the Nucleus' CELL 140, (4) 477-490 , DOI
(2010) 'Acquired rippling muscle disease in association with myasthenia gravis' JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 81, (1) 125-126 , DOI
(2010) 'Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244' Neurobiol Dis 37, (1) 141-146 , DOI
(2010) 'The epidemiology of motor neurone disease in two counties in the southwest of England' Journal of Neurology Publisher Site
(2010) 'ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma' Neuro Onc 12, 834-843
(2009) 'Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ' Histopathology 55, (6) 744-749 , DOI
(2009) 'Aquired neuromyotonia following upper respiratory tract infection' Case J 2, 7952-7952 Open access
(2009) 'Acquired neuromyotonia following upper respiratory tract infection: a case report' Cases J 2, , DOI Open access
(2009) 'Acquired neuromyotonia following upper respiratory tract infection: A case report' Cases Journal 2, (9) , DOI
(2009) 'PAK kinase regulates Rac GTPase and is a potential target in human schwannomas' Exp Neurol 218, (1) 137-144 , DOI
(2009) 'Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma' Brain Pathol 19, (1) 27-38 , DOI
(2008) 'High concentrations of cannabinoids activate apoptosis in human U373MG glioma cells' J Neurosci Res 86, (14) 3212-3220 , DOI
(2008) 'Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma' Cancer Res 68, (13) 5236-5245 , DOI
(2008) 'Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells' Glia 56, (5) 506-515 , DOI
(2007) 'Neurofibromatosis type 1 with involvement of the enteric nerves' J Neurol Neurosurg Psychiatry 78, (10) 1163-1164 , DOI
(2007) 'Actin-rich protrusions and nonlocalized GTPase activation in Merlin-deficient schwannornas' JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY 66, (7) 608-616 , DOI
(2007) 'Role of NF2 Haploinsufficiency in NF2-associated Polyneuropathy' Brain Pathology 0, (0) 371-376 , DOI
(2007) 'Axonale Neuropathie und Auffälligkeiten der mitochondrialen tRNA bei einem Patienten mit benigner symmetrischer Lipomatose' Klinische Neurophysiologie 38, (01) , DOI
(2007) 'Actin-rich protrusions and non-localised GTPase activation in merlin-deficient schwannomas' NEURON GLIA BIOLOGY 2, S123-S123
(2007) 'Actin-rich protrusions and nonlocalized GTPase activation in Merlin-deficient schwannornas' Journal of Neuropathology and Experimental Neurology 66, (7) 608-616
(2007) 'Central core myopathy. A juvenile and adult disease' Nervenarzt 78, (4) 387-+
(2007) 'Like to move it? Actin-rich protrusions, migration and adhesion in schwannoma, a benign tumour of the nervous system' Neuropathology and Applied Neurobiology 33, (2) 259-259
(2007) 'Neurofibromatosis type 1 with involvement of the enteric nerves' Journal of Neurology Neurosurgery and Psychiatry 78, (10) 1163-1164
(2007) 'Pathobiology of schwannomas' Journal of Neurology Neurosurgery and Psychiatry 78, (2)
(2007) 'Strong and long-lasting activation of ERK in human schwannoma cells' Neuropathology and Applied Neurobiology 33, (2) 258-259
(2007) 'Actin-rich protrusions and non-localised GTPase activation in merlin-deficient schwannomas' Neuron Glia Biology 2, S123-S123
(2007) 'Role of NF2 haploinsufficiency in NF2-associated polyneuropathy' Brain Pathology 17, (4) 371-376
(2007) 'Electronic signatures for copyright in the UK: a solution to the "holy grail" of document delivery' Interlending and Document Supply 35, (1) 15-20 , DOI Open access
(2006) 'Benign symmetric lipomatosis with axonal neuropathy and abnormalities in specific mitochondrial tRNA regions' Eur J Med Res 11, (12) 545-546
(2006) 'Differential gene expression between human schwannoma and control Schwann cells' NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY 32, (6) 605-614 , DOI
(2006) 'News on the genetics, epidemiology, medical care and translational research of Schwannomas' JOURNAL OF NEUROLOGY 253, (12) 1533-1541 , DOI
(2006) 'A functional association between merlin and HEI10, a cell cycle regulator' ONCOGENE 25, (32) 4389-4398 , DOI
(2006) 'Insights from the development of Schwann cell tumours' Neuromuscular Disorders 16, S105-S106
(2006) 'News on the genetics, epidemiology, medical care and translational research of Schwannomas' Journal of Neurology 253, (12) 1533-1541
(2006) 'Practical Issues: Copyright for Clinical Teachers' The Clinical Teacher 3, (1) 60-64 Publisher Site
(2005) 'Motor protein diseases of the nervous system' AMYOTROPHIC LATERAL SCLEROSIS AND OTHER MOTOR NEURON DISORDERS 6, (4) 197-201 , DOI
(2005) 'Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD' ANNALS OF NEUROLOGY 58, (5) 777-780 , DOI
(2005) 'Die Rolle von PAK in der Pathophysiologie humaner Schwannome: ein zukünftiges therapeutisches Target?' Aktuelle Neurologie 32, (S 4) , DOI
(2005) 'Laryngospasmus bei x-chromosomaler Spinobulbärer Muskelatrophie (Kennedy-Syndrom)' Aktuelle Neurologie 32, (S 4) , DOI
(2005) 'Heterozygous R1101K mutation of the DCTN1 gene in a family with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)' EUROPEAN JOURNAL OF NEUROLOGY 12, 27-27
(2005) 'Fludeoxyglucose F 18 positron emission tomography and computed tomography of a giant retroperitoneal schwannoma occurring in a patient with neurofibromatosis type 2' ARCHIVES OF NEUROLOGY 62, (4) 674-675 , DOI
(2005) 'Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228' CANCER BIOLOGY & THERAPY 4, (4) 379-381
(2005) 'Laryngospasm: An underdiagnosed symptom of X-linked spinobulbar muscular atrophy' NEUROLOGY 64, (4) 753-754 , DOI
(2005) 'Sensitive detection of deletions of one or more exons in the neurofibromatosis type 2 (NF2) gene by multiplexed gene dosage polymerase chain reaction' JOURNAL OF MOLECULAR DIAGNOSTICS 7, (1) 97-104 , DOI
(2005) 'Fludeoxyglucose F 18 positron emission tomography and computed tomography of a giant retroperitoneal schwannoma occurring in a patient with neurofibromatosis type 2' Archives of Neurology 62, (4) 674-675
(2005) 'Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD' Annals of Neurology 58, (5) 777-780
(2005) 'Heterozygous R1101K mutation of the DCTN1 gene in a family with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)' European Journal of Neurology 12, 27-27
(2005) 'Laryngospasm: An underdiagnosed symptom of X-linked spinobulbar muscular atrophy' Neurology 64, (4) 753-754
(2005) 'Motor protein diseases of the nervous system' Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 6, (4) 197-201
(2005) 'MR-Pathologic comparison of the upper spinal cord in different motor neuron diseases' EUROPEAN NEUROLOGY 53, (2) 74-77 , DOI
(2005) 'MR-Pathologic comparison of the upper spinal cord in different motor neuron diseases' European Neurology 53, (2) 74-77
(2005) 'Rearrangements of the intermediate filament GFAP in primary human schwannoma cells' NEUROBIOLOGY OF DISEASE 19, (1-2) 1-9 , DOI
(2005) 'Rearrangements of the intermediate filament GFAP in primary human schwannoma cells' Neurobiology of Disease 19, (1-2) 1-9
(2005) 'Reduced apoptosis rates in human schwannomas' BRAIN PATHOLOGY 15, (1) 17-22
(2005) 'Reduced apoptosis rates in human schwannomas' Brain Pathology 15, (1) 17-22
(2005) 'Sensitive detection of deletions of one or more exons in the neurofibromatosis type 2 (NF2) gene by multiplexed gene dosage polymerase chain reaction' Journal of Molecular Diagnostics 7, (1) 97-104
(2005) 'Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228' Cancer Biology & Therapy 4, (4) 379-381
(2005) 'Heterozygous R1101K mutation of the DCTN1 gene in a family with amyotrophic lateral sclerosis and frontotemporal dementia' Journal of Neurology 252, 18-18
(2004) 'Complicated hereditary spastic paraplegia with thin corpus callosum: Variation of phenotypic expression over time' JOURNAL OF NEUROLOGY 251, (10) 1285-1287 , DOI
(2004) 'Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS' NEUROLOGY 63, (4) 724-726 , DOI
(2004) 'FKRP (826C > A) frequently causes limb-girdle muscular dystrophy in German patients' JOURNAL OF MEDICAL GENETICS 41, (4) , DOI
(2004) 'A clue to the therapy of neurofibromatosis type 2: NF2/Merlin is a PAK1 inhibitor' CANCER JOURNAL 10, (1) 20-26 , DOI
(2004) 'A clue to the therapy of neurofibromatosis type 2: NF2/Merlin is a PAK1 inhibitor' Cancer Journal 10, (1) 20-26
(2004) 'FKRP (826C > A) frequently causes limb-girdle muscular dystrophy in German patients' Journal of Medical Genetics 41, (4)
(2004) 'Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS' Neurology 63, (4) 724-726
(2004) 'Point mutations of the p150 subunit of dynactin (DCTN1) gene in amyotrophic lateral sclerosis' Annals of Neurology 56, S30-S30
(2004) 'Complicated hereditary spastic paraplegia with thin corpus callosum: Variation of phenotypic expression over time' Journal of Neurology 251, (10) 1285-1287
(2004) 'FKRP (826C > A) frequently causes limb-girdle muscular dystrophy in German patients' Journal of Neurology 251, 15-15
(2004) 'Point mutations of the p150 subunit of dynactin (DCTN1) and absence of mutations in the cytoplasmic dynein heavy chain (DNCHC1) gene in amyotrophic lateral sclerosis' Journal of Neurology 251, 33-33
(2004) 'Heterozygote Punktmutationen in der p150 Untereinheit des Dynactin-Gens bei der amyotrophen Lateralsklerose' Aktuelle Neurologie 31, (S 1) , DOI
(2004) 'Klinische und kernspintomographische Verlaufsuntersuchung bei Patienten mit einer komplizierten hereditären spastischen Paraparese und dünnem Corpus callosum' Aktuelle Neurologie 31, (S 1) , DOI
(2004) 'Neurofibromatose Typ 2: Charakterisierung einer hereditären Tumorerkrankung' Aktuelle Neurologie 31, (S 1) , DOI
(2003) 'A novel nonsense mutation in the ABC1 gene causes a severe syringomyelia-like phenotype of Tangier disease (vol 126, pg 920, 2003)' BRAIN 126, 2115-2115
(2003) 'Pathological adhesion of primary human schwannoma cells is dependent on altered expression of integrins' BRAIN PATHOLOGY 13, (3) 352-363
(2003) 'ALS/MND meeting of the European AlS/MND group Reisensburg Castle 30 January - 1 February 2003' Amyotroph Lateral Scler Other Motor Neuron Disord 4, (2) 121-122 , DOI
(2003) 'ALS/MND meeting of the European ALS/MND group Reisensburg Castle 30 January - 1 February 2003' Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 4, (2) 121-122 , DOI
(2003) 'Quinidine impairs proliferation of neurofibromatosis type 2-deficient human malignant mesothelioma cells' CANCER 97, (8) 1955-1962 , DOI
(2003) 'A novel nonsense mutation in the ABC1 gene causes a severe syringomyelia-like phenotype of Tangier disease' BRAIN 126, 920-927 , DOI
(2003) 'Transient, recurrent, white matter lesions in x-linked Charcot-Marie-Tooth disease with novel connexin 32 mutation' ARCHIVES OF NEUROLOGY 60, (4) 605-609 , DOI
(2003) 'Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells' Human Molecular Genetics 12, (11) 1211-1221 , DOI
(2003) 'A novel nonsense mutation in the ABC1 gene causes a severe syringomyelia-like phenotype of Tangier disease' Brain 126, 920-927
(2003) 'Pathological adhesion of primary human schwannoma cells is dependent on altered expression of integrins' Brain Pathology 13, (3) 352-363
(2003) 'Quinidine impairs proliferation of neurofibromatosis type 2-deficient human malignant mesothelioma cells' Cancer 97, (8) 1955-1962
(2003) 'Tetracycline-inducible transgene expression mediated by a single AAV vector' Gene Therapy 10, (1) 84-94
(2003) 'Tetracycline-inducible transgene expression mediated by a single AAV vector' GENE THERAPY 10, (1) 84-94 , DOI
(2003) 'Transient, recurrent, white matter lesions in x-linked Charcot-Marie-Tooth disease with novel connexin 32 mutation' Archives of Neurology 60, (4) 605-609
(2003) 'Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells' Human Molecular Genetics 12, (11) 1211-1221
(2002) 'X-linked bulbospinal neuronopathy - Kennedy disease' ARCHIVES OF NEUROLOGY 59, (12) 1921-1926 , DOI
(2002) 'Hereditary motor neuropathies and motor neuron diseases: which is which' Amyotroph Lateral Scler Other Motor Neuron Disord 3, (4) 186-189 , DOI
(2002) 'Secondary axon atrophy and neurological dysfunction in demyelinating neuropathies' CURRENT OPINION IN NEUROLOGY 15, (5) 611-615 , DOI
(2002) 'Axon damage in CMT due to mutation in myelin protein P0 (vol 11, pg 753, 2001)' NEUROMUSCULAR DISORDERS 12, (4) 432-432 , DOI
(2002) 'Enhanced adhesion of Schwannoma cells is dependent on an increased expression of the integrin alpha 6, beta 1 and beta 4 chains in vitro' GLIA S31-S31
(2002) 'Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2' Brain 125, (5) 996-1004 , DOI
(2002) 'Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis' Human Molecular Genetics 11, (1) 69-76 , DOI
(2002) 'Axon damage in CMT due to mutation in myelin protein P0 (vol 11, pg 753, 2001)' Neuromuscular Disorders 12, (4) 432-432
(2002) 'Novel point mutation of the ABC1 gene in Tangier disease with severe syringomyelia-like phenotype and unique endoneurial sclerosis' Journal of the Neurological Sciences 199,
(2002) 'Occurrence and characterisation of peripheral nerve involvement in neurofibromatosis type 2' Journal of the Neurological Sciences 199,
(2002) 'Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2' Brain 125, 996-1004
(2002) 'Secondary axon atrophy and neurological dysfunction in demyelinating neuropathies' Current Opinion in Neurology 15, (5) 611-615
(2002) 'Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis' Human Molecular Genetics 11, (1) 69-76
(2002) 'X-linked bulbospinal neuronopathy - Kennedy disease' Archives of Neurology 59, (12) 1921-1926
(2002) 'X-linked bulbospinal neuronopathy Kennedy: Presence of known and unknown clinical features and electrophysiological investigation in 34 cases' Journal of the Neurological Sciences 199,
(2002) 'Enhanced adhesion of Schwannoma cells is dependent on an increased expression of the integrin alpha 6, beta 1 and beta 4 chains in vitro' Glia S31-S31
(2001) 'Spinal neurofibromatosis without cafe-au-lait macules in two families with null mutations of the NF1 gene' AMERICAN JOURNAL OF HUMAN GENETICS 69, (6) 1395-1400 , DOI
(2001) 'Axon damage in CMT due to mutation in myelin protein P0' NEUROMUSCULAR DISORDERS 11, (8) 753-756 , DOI
(2001) 'Hereditary demyelinating neuropathies: from gene to disease' NEUROGENETICS 3, (2) 53-57 , DOI
(2001) 'Enhanced Proliferation and Potassium Conductance of Schwann Cells Isolated from NF2 Schwannomas Can Be Reduced by Quinidine' Neurobiology of Disease 8, (1) 181-181 , DOI
(2001) 'Axon damage in CMT due to mutation in myelin protein P0' Neuromuscular Disorders 11, (8) 753-756
(2001) 'Hereditary demyelinating neuropathies: from gene to disease' Neurogenetics 3, (2) 53-57
(2001) 'Spinal neurofibromatosis without cafe-au-lait macules in two families with null mutations of the NF1 gene' American Journal of Human Genetics 69, (6) 1395-1400
(2000) 'Enhanced Proliferation and Potassium Conductance of Schwann Cells Isolated from NF2 Schwannomas Can Be Reduced by Quinidine' Neurobiology of Disease 7, (6) 691-691 , DOI
(2000) 'MUTATION-DEPENDENT ALTERATION IN CELLULAR DISTRIBUTION OF PERIPHERAL MYELIN PROTEIN 22 IN NERVE BIOPSIES FROM CHARCOT-MARIE-TOOTH TYPE 1A' Journal of the Peripheral Nervous System 5, (4) 251-251 , DOI
(2000) 'MUTATION‐DEPENDENT ALTERATION IN CELLULAR DISTRIBUTION OF PERIPHERAL MYELIN PROTEIN 22 IN NERVE BIOPSIES FROM CHARCOT‐MARIE‐TOOTH TYPE 1A' Journal of the Peripheral Nervous System 5, (4) 251-251 , DOI
(2000) 'Long-term culture and characterization of human neurofibroma-derived Schwann cells' JOURNAL OF NEUROSCIENCE RESEARCH 61, (5) 524-532 , DOI
(2000) 'Enhanced proliferation and potassium conductance of schwann cells isolated from NF2 schwannomas can be reduced by quinidine' NEUROBIOLOGY OF DISEASE 7, (4) 483-491 , DOI
(2000) 'Autosomal aneuploidy rate in spermatozoa: a comparison between normospermic and oligospermic males, using a double-color FISH' Immuno-analyse & Biologie Spécialisée 15, (4) 262-266 , DOI
(2000) 'Mutation-dependent alteration in cellular distribution of peripheral myelin protein 22 in nerve biopsies from Charcot-Marie-Tooth type 1A' BRAIN 123, 1001-1006 , DOI
(2000) 'Long-term culture and characterization of human neurofibroma-derived Schwann cells' Journal of Neuroscience Research 61, (5) 524-532 , DOI
(1999) 'Muscle injury in Guillain-Barre syndrome: a case report' JOURNAL OF NEUROLOGY 246, (12) 1207-1208 , DOI
(1999) 'Cellular contaminants of adeno-associated virus vector stocks can enhance transduction' GENE THERAPY 6, (6) 1045-1053 , DOI
(1999) 'Neuroligand-mediated calcium signaling in cultured human schwannoma cells' JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM 4, (2) 99-105
(1998) 'Placebo-controlled multicentre randomised trial of interferon ß-1b in treatment of secondary progressive multiple sclerosis' The Lancet 352, (9139) 1491-1497 , DOI
(1998) 'Major histocompatibility complex class II expression and macrophage responses in genetically proven Charcot-Marie-Tooth type 1 and hereditary neuropathy with liability to pressure palsies' MUSCLE & NERVE 21, (11) 1419-1427 , DOI
(1998) 'Voltage-dependent membrane currents of cultured human neurofibromatosis type 2 Schwann cells' GLIA 24, (3) 313-322 , DOI
(1998) 'Voltage-dependent membrane currents of cultured human neurofibromatosis type 2 Schwann cells' Glia 24, (3) 313-322 , DOI
(1998) 'Major histocompatibility complex class II expression and macrophage responses in genetically proven Charcot-Marie-Tooth type 1 and hereditary neuropathy with liability to pressure palsies' Muscle and Nerve 21, (11) 1419-1427 , DOI
(1998) 'Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients' NEUROBIOLOGY OF DISEASE 5, (1) 55-64 , DOI
(1998) 'Pathogenesis of Charcot-Marie-Tooth IA (CMTIA) neuropathy' TRENDS IN NEUROSCIENCES 21, (7) 282-286 , DOI
(1998) 'Improved culture methods to expand schwann cells with altered growth behaviour from CMT1A patients' GLIA 23, (2) 89-98 , DOI
(1998) 'Improved culture methods to expand schwann cells with altered growth behaviour from CMT1a patients' GLIA 23, (2) 89-98 , DOI
(1997) 'Lack of immune responses to immediate or delayed implanted allogeneic and xenogeneic Schwann cell suspensions' GLIA 21, (3) 299-314
(1997) 'Lack of immune responses to immediate or delayed implanted allogeneic and xenogeneic Schwann cell suspensions' Glia 21, (3) 299-314 , DOI
(1997) 'Lack of immune responses to immediate or delayed implanted allogeneic and xenogeneic Schwann cell suspensions' Glia 21, (3) 299-314 , DOI
(1997) 'Schwann cell differentiation in Charcot-Marie-Tooth disease type 1A (CMT1A): normal number of myelinating Schwann cells in young CMT1A patients and neural cell adhesion molecule expression in onion bulbs' ACTA NEUROPATHOLOGICA 94, (4) 310-315 , DOI
(1997) 'Congenital axonal neuropathy caused by deletions in the spinal muscular atrophy region' ANNALS OF NEUROLOGY 42, (3) 364-368 , DOI
(1997) 'Peripheral myelin protein 22kD (PMP22): Structure, function and role in demyelinating hereditary neuropathies' JOURNAL OF NEUROCHEMISTRY 69, S94-S94
(1997) 'Advances in Charcot-Marie-Tooth disease research: cellular function of CMT-related proteins, transgenic animal models, and pathomechanisms. The European CMT Consortium' Neurobiol Dis 4, (3-4) 215-220 , DOI
(1996) 'Low affinity NGF receptor expression in CMT1A nerve biopsies of different disease stages' BRAIN 119, 1461-1469 , DOI
(1996) 'Characterization of basal ganglia dysfunction in Leber 'plus' disease' JOURNAL OF NEUROLOGY 243, (3) 297-300 , DOI
(1996) 'Estimation of the Mutation Frequencies
in Charcot-Marie-Tooth Disease Type 1
and Hereditary Neuropathy with
Liability to Pressure Palsies:
A European Collaborative Study' European Journal of Human Genetics 4, (1) 25-33 , DOI
(1994) 'PERIPHERAL MYELIN PROTEIN-22 EXPRESSION IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A SURAL NERVE BIOPSIES' JOURNAL OF NEUROSCIENCE RESEARCH 37, (5) 654-659 , DOI
(1993) 'BALO CONCENTRIC SCLEROSIS FOLLOWED BY MRI AND POSITRON EMISSION TOMOGRAPHY' NEURORADIOLOGY 35, (8) 578-580 , DOI
(1993) 'EXPRESSION OF DECORIN MESSENGER-RNA IN THE NERVOUS-SYSTEM OF RAT' JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY 41, (9) 1383-1391 , DOI
(1993) 'Balo's concentric sclerosis followed by MRI and positron emission tomography' Neuroradiology 35, (8) 578-580 , DOI
(1992) 'MOLECULAR UNDERSTANDING AND DNA TEST FOR CHARCOT-MARIE-TOOTH DISEASE IN SIGHT' AKTUELLE NEUROLOGIE 19, (6) 182-184 , DOI
(1992) 'PERIPHERAL MYELIN PROTEIN-22 GENE MAPS IN THE DUPLICATION IN CHROMOSOME-17P11.2 ASSOCIATED WITH CHARCOT-MARIE-TOOTH-1A' NATURE GENETICS 1, (3) 176-179 , DOI
(1992) 'THE PERIPHERAL MYELIN PROTEIN GENE PMP-22 IS CONTAINED WITHIN THE CHARCOT-MARIE-TOOTH DISEASE TYPE-1A DUPLICATION' NATURE GENETICS 1, (3) 171-175 , DOI
(1991) 'AXON-REGULATED EXPRESSION OF A SCHWANN-CELL TRANSCRIPT THAT IS HOMOLOGOUS TO A GROWTH ARREST-SPECIFIC GENE' EMBO JOURNAL 10, (12) 3661-3668 , DOI
(1990) 'Recurrent hematomas following craniotomy for traumatic intracranial mass' J Neurosurg 72, (1) 9-14 , DOI
'ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma' Neuro-oncology Publisher Site , DOI Open access
Letters
(2012) 'The tumor suppressor merlin controls growth in its open state, and phosphorylation converts it to a less-active more-closed state' Dev Cell 22, (4) 703-705 , DOI
Chapters
(2010) 'Receptor Tyrosine Kinases in Human Schwannoma' Angiogenesis &amp Therapeutic Targets In Cancer BENTHAM SCIENCE PUBLISHERS 90-98 , DOI
(2009) 'Neuropathies, Inherited Peripheral' Encyclopedia of Molecular Mechanisms of Disease Springer Berlin Heidelberg 1461-1467 , DOI
Conference Papers
(2018) 'High miR-9 levels represent a novel prognostic biomarker to predict development of malignant meningioma' 25th Biennial Congress of the European Association for Cancer Research (EACR25) Amsterdam 6-/-0/20187-/-0/2018Open access
(2016) 'ANALYSIS OF THE PROTEOM AND PHOSHOPROTEOM OF MENINGIOMAS' 68-68
(2016) 'Identification of novel molecular targets in stratified meningiomas using a proteomic approach' 20-20
(2015) 'GROWTH FACTOR SIGNALLING PATHWAYS IN MENINGIOMAS IS COMMON AND PARTLY DEPENDS ON SUBTYPE ALLOWING FOR STRATIFICATION' 14-14
(2015) 'Abstract 704: Scaffold protein KSR1 is negatively regulated by merlin and promotes tumor development in merlin deficient tumors' American Association for Cancer Research (AACR) 704-704 , DOI
(2014) 'Abstract 2609: The role of focal adhesion kinase (FAK), PI3K/AKT and p53/mouse double minute 2 homologue (MDM2) complex in the pathobiology of Merlin-deficient tumors' American Association for Cancer Research (AACR) 2609-2609 , DOI
(2014) 'ACTIVATION OF MULTIPLE GROWTH FACTOR SIGNALLING PATHWAYS IS FREQUENT IN MENINGIOMAS'
(2014) 'Growth factor signaling pathway activation in meningiomas' 101-101
(2013) 'THE ROLE OF MERLIN ISOFORM 2 IN NEUROFIBROMATOSIS TYPE 2-ASSOCIATED POLYNEUROPATHY' S104-S104
(2013) 'Tumour suppressor merlin regulates thrombospondin 1 signalling via CD47' 381-381
(2013) 'Activation of multiple signalling pathways in meningiomas is unrelated to NF2 gene status' 35-35
(2012) 'ENDOCANNABINOID TOXICITY IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE' BMJ A13.4-A14 , DOI
(2012) 'EXPRESSION OF C-JUN & SOX-2 IN HUMAN SCHWANNOMAS AND TRAUMATIC NEUROMAS' 9-10
(2012) 'MERLIN DEFICIENT HUMAN TUMOURS SHOW LOSS OF CONTACT INHIBITION, ACTIVATION OF WNT/beta-CATENIN SIGNALING LINKED TO THE PDGFR/SRC AND RAC/PAK PATHWAYS' 5-6
(2012) 'Delta(9)-THC is protective in a cell culture model of Parkinson's disease through a PPAR gamma mediated mechanism resulting in increased expression of PGC1-alpha' S39-S39
(2012) '108 Investigating the neuroprotective properties of Δ9-THC in a cell culture model of Parkinson's disease' BMJ e1.58-e1 , DOI
(2012) 'Emerging Therapeutic Targets in Merlin-Deficient Tumors' S18-S18
(2011) 'Acquired rippling muscle disease-report of two cases' 29-29
(2011) 'GAS6/AXL-FAMILY RECEPTORS IN SCHWANNOMA PATHOLOGICAL PROLIFERATION, ADHESION AND SURVIVAL' 1-1
(2010) 'CANNABINOIDS ARE NEUROPROTECTIVE IN A HUMAN CELL CULTURE MODEL OF PARKINSON'S DISEASE' E60-E60 , DOI
(2010) 'CHANGES IN IRON-REGULATORY GENE EXPRESSION OCCUR IN HUMAN CELL CULTURE MODELS OF PARKINSON'S DISEASE' E29-E29 , DOI
(2010) 'IGF/IGFBP SIGNALING IN MERLIN-DEFICIENT TUMORS' 22-22
(2009) 'Abstract C164: Targeting receptor tyrosine kinases and their downstream signaling pathways in human schwannoma' American Association for Cancer Research (AACR) C164-C164 , DOI
(2009) 'THE EPIDEMIOLOGY OF MOTOR NEURONE DISEASE IN TWO COUNTIES IN THE SOUTH WEST OF ENGLAND' , DOI
(2009) 'REGULATION OF CELL DIFFERENTIATION IN MERLIN NULL TUMOURS' S170-S170
(2009) 'EGF RECEPTOR FAMILY ACTIVATION AND LAPATINIB IN VESTIBULAR SCHWANNOMA' 577-578
(2009) 'Cannabinoid receptors expression in multiple sclerosis' 17-17
(2007) 'Strong and long-lasting activation of ERK in human schwannoma cells' 258-259
(2007) 'Pathobiology of schwannomas' 214-214
(2007) 'Non-localised Rac1 and Cdc42 activation and protrusive activity in schwannoma, a benign tumour of the nervous system' 107-112
(2007) 'Non-localised Rac1 and Cdc42 activation and protrusive activity in schwannoma, a benign tumour of the nervous system' Proceedings of the Viii European Meeting on Glial Cells in Health and Disease 107-112
(2006) 'Heterozygous R1101K mutation of the DCTN1 gene in a family with frontotemporal dementia and amyotrophic lateral sclerosis' S64-S64
(2006) 'Insights from the development of Schwann cell tumours' S105-S106
(2005) 'Heterozygous R1101K mutation of the DCTN1 gene in a family with amyotrophic lateral sclerosis and frontotemporal dementia' 18-18
(2004) 'FKRP (826C > A) frequently causes limb-girdle muscular dystrophy in German patients' 15-15
(2004) 'Point mutations of the p150 subunit of dynactin (DCTN1) and absence of mutations in the cytoplasmic dynein heavy chain (DNCHC1) gene in amyotrophic lateral sclerosis' 33-33
(2003) 'ALS/MND meeting of the European ALS/MND group Reisenburg Castle 30 January - 1 February 2003' 121-122 , DOI
(2002) 'A novel nonsense mutation in the ABC1 gene causes a severe syringomyelia-like phenotype of Tangier disease' 577-578
(2002) 'Occurrence and characterisation of peripheral nerve involvement in neurofibromatosis type 2' S60-S60
(2002) 'X-linked bulbospinal neuronopathy Kennedy: Presence of known and unknown clinical features and electrophysiological investigation in 34 cases' S76-S77
Presentations and posters
'Cannabinoids Are Neuroprotective in a Human Cell Culture Model of Parkinson's Disease' Open access
'Abstract 1164: Human endogenous retrovirus type K promotes proliferation of Merlin negative schwannoma and meningioma which can be inhibited by anti-retroviral and anti-TEAD drugs' , DOI
'Abstract 941: TAM receptors as potential therapeutic targets in NF2-related schwannomas and meningiomas' , DOI
'BIOM-56. MIR-497 AND 219 IN BLOOD AID MENINGIOMA CLASSIFICATIONMIR-497 AND 219 IN BLOOD AID MENINGIOMA CLASSIFICATION' , DOI
'Circulating miR-9 levels as a novel prognostic biomarker for highergrade meningioma' Open access
'CSIG-27. PROTEOMIC ANALYSIS OF GENETICALLY STRATIFIED MENINGIOMA' , DOI
'EXTH-90. HDAC INHIBITOR, CAY10603, IS A POTENT RADIOSENSITIZER IN MENINGIOMAS' , DOI
'HIGH LEVELS OF GATA-4 IN MALIGNANT MENINGIOMA LEAD TO LOWER miR-497 similar to 195 CLUSTER EXPRESSION IN TISSUE AND BLOOD'
'Human Endogenous Retrovirus Type K promotes proliferation of Merlin-negative schwannoma and meningioma which can be inhibited by anti-retroviral and anti-TEAD drugs' , DOI Open access
'INVESTIGATING THE ROLE OF TAM FAMILY RECEPTORS IN MERLIN DEFICIENT TUMOURS'
'PROTEOME AND PHOSPHOPROTEOME ANALYSIS IDENTIFIES STAT1 AS A NOVEL TARGET IN DIFFERENT GRADE MENINGIOMAS' , DOI Open access
'MNGI-07. THE ANAPLASTIC MENINGIOMA INTERNATIONAL CONSORTIUM (AMICo) RETROSPECTIVE STUDY OF TREATMENT AND OUTCOME OF PATIENTS WITH ANAPLASTIC MENINGIOMAS' , DOI
'A pilot study to establish non-invasive biomarkers for higher-grade meningioma' , DOI
'Identifying novel molecular differences between WHO grade I and II meningiomas' , DOI
'OPTC-1. Proteomic analysis of genetically stratified low-grade meningioma' , DOI
'OS08.5.A Proteomic analysis of meningioma' , DOI
'P02.09 Proteomic analysis of meningioma discovers new pathways and their activation including NEK9 and AKT' , DOI
'P11.12 Analysis of the proteom and phoshoproteom of meningiomas' , DOI
'P09.07 Constitutive activation of the EGFR-STAT1 axis increases proliferation of meningioma tumour cells' , DOI
'P12.08 Proteome and phosphoproteome analysis identifies STAT1 as a novel target in different grade meningiomas' , DOI
'PO-162 The transcription factor GATA4 is overexpressed in malignant meningioma enhancing proliferation via downregulation of miR-15 family members' , DOI
'PO-522 Global proteome and phosphoprotein profiling of meningiomas reveals novel potential therapeutic targets and biomarkers' , DOI
'Proteomic analysis of genetically stratified low-grade meningioma' , DOI
'Proteomic analysis of genetically stratified meningioma' , DOI
'PROTEOMIC ANALYSIS OF MENINGIOMA DISCOVERS NEW PATHWAYS AND THEIR ACTIVATION INCLUDING NEK9 AND AKT'
'TARGETING CONSTITUTIVE ACTIVATION OF THE EGFR-STAT1 AXIS DECREASES PROLIFERATION OF MENINGIOMA TUMOUR CELLS'
'THE ANAPLASTIC MENINGIOMA INTERNATIONAL CONSORTIUM (AMICo) RETROSPECTIVE STUDY OF TREATMENT AND OUTCOME OF PATIENTS WITH ANAPLASTIC MENINGIOMAS'
'The cancer stem cell marker ALDH1A1 is upregulated and drives proliferation in merlin null meningioma and schwannoma'
'The potential of CRL4DCAF1 and KSR1 as therapeutic targets in merlin-deficient meningioma' , DOI Open access
'The transcription factor GATA4 is overexpressed in malignant meningioma enhancing proliferation via downregulation of miR-15 family members' Open access
Other Publications
Data from Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. , DOI
Figure S1 from Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. , DOI
Figure S1 from Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. , DOI
Figure S2 from Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. , DOI
Figure S2 from Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. , DOI
Figure S3 from Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. , DOI
Figure S3 from Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. , DOI
Figure S4 from Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. , DOI
Figure S4 from Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. , DOI
Figure S5 from Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. , DOI
Figure S5 from Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. , DOI
Figure S6 from Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. , DOI
Figure S6 from Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. , DOI
Figure S7 from Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. , DOI
Figure S7 from Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. , DOI
Supplementary Table 1 from Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. , DOI
Supplementary Table 1 from Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. , DOI
Supplementary Table 2 from Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. , DOI
Supplementary Table 2 from Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. , DOI
Supplementary Table 3 from Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. , DOI
Supplementary Table 3 from Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. , DOI